The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Name on ClinicalTrials.gov (link is external) | A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (SMR-2984) |
|---|---|
| Study Drug | alginate oligosaccharide |
| Type of Study Drug | Mucus Alteration |
| Study Title | A double-blind, randomised, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis. |
| Study Phase | 2b |
| Study Sponsor | Algipharma |
http://clinicaltrials.gov/ct2/show/NCT02157922 (link is external) | |
| Participating ECFS-CTN sites | Denmark: Copenhagen Germany: Berlin, Frankfurt, Hannover, Cologne, Munchen Sweden: Gothenburg, Stockholm UK: Belfast, London, Nottingham |
| Age | 18 years and older |